Skip to main content

Table 3 Baseline Characteristics of CHC, GT1 and IL28B-CC patients

From: CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV

Variables

Overall

NR (11)a

non-NR (34)a

P value

Age (years)

59.60 ± 8.62

60.00 ± 7.01

59.47 ± 9.17

0.862

Male (%)

60.0

63.6

58.8

0.725

BMI (Kg/m2)

25.24 ± 3.01

25.56 ± 3.39

25.14 ± 2.92

0.693

AST (U/L)

75.76 ± 35.93

85 ± 42

73 ± 34

0.313

ALT (U/L)

98.82 ± 55.79

104 ± 56

97 ± 56

0.741

HCV RNA (log10 IU/ml)

2.39(6.22)b

4.09(12.27)b

3.97(5.56)b

0.927

Diabetes Mellitus (%)

26.7

13.6

32.3

0.072

Liver cirrhosis (%)

24.4

45.5

17.6

0.039

  1. anumber of patients shown in parentheses
  2. bmedian (IQR) shown in parentheses
  3. Data are shown as mean ± standard deviation. Statistic analysis was done by Mann-Whitney test for comparison. Significant P values are shown in bold. AST, aspartate aminotransferase; ALT, alanine aminotransferase; HCV, hepatitis C virus; IL28B, Interleukin-28B